Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - rocuronium bromide, quantity: 100 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - rocuronium bromide, quantity: 50 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; sodium hydroxide; water for injections - adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age. adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children. adjunct in the intensive care unit (icu) to facilitate mechanical ventilation.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - metronidazole, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate dodecahydrate; water for injections; citric acid monohydrate - metronidazole baxter intravenous infusion is indicated for treatment of anaerobic infections in patients for whom oral administration is not possible. where immediate anti-anaerobic chemotherapy is required. where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia. note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - aprotinin acetate; calcium chloride dihydrate; human fibrinogen; human thrombin - solutions for sealant - calcium chloride dihydrate 40 mcmol/ml; human thrombin 500 iu / 1 ml; aprotinin acetate 3000 kiu / 1 ml; human fibrinogen 91 mg / 1 ml - combinations - supportive treatment in adults and children from 1 month of age where standard surgical techniques appear insufficient: * for improvement of hemostasis.* as a tissue glue to improve wound healing or to support sutures in vascular surgery and in gastrointestinal anastomoses.* for tissue sealing, to improve adhesion of the separated tissue (e.g. tissue flaps, grafts, split skin grafts [mesh grafts]).efficacy in fully heparinized patients has been proven.

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - glucose monohydrate; sodium chloride - solution for infusion - glucose monohydrate 5.5 %w/v; sodium chloride 0.33 %w/v - electrolytes with carbohydrates - a source of water, electrolytes and calories

Israel - engelsk - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose anhydrous as monohydrate; lactic acid; magnesium chloride hexahydrate; potassium chloride; sodium chloride; sodium hydrogen carbonate - solution for heamodialysis/haemofiltration - calcium chloride dihydrate 5.145 g/l; magnesium chloride hexahydrate 2.033 g/l; glucose anhydrous as monohydrate 22.00 g/l; lactic acid 5.400 g/l; sodium chloride 6.45 g/l; sodium hydrogen carbonate 3.090 g/l; potassium chloride 0.157 g/l - combinations - prismasol 2 mmol/l potassium is used in the treatment of renal failure, as substitution solution in haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis or continuous haemodiafiltration. prismasol 2 mmol/l potassium solution may also be used in case of drug poisoning with dialysable or filterable substances. prismasol 2 mmol/l potassium solution is indicated in patients who have tendency to hyperkalaemia.